GlassScriptPhysician profile
Elizabeth Michelle
NPI 1457655318
$2,219.19
in general payments reported to CMS, 2019-2025
33 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $46.14 · 2021: $335 · 2022: $355 · 2023: $471 · 2024: $355 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.79 | 2021-2025 | |
| Ucb, INC. | $182.94 | 2021-2025 | Briviact, Rystiggo |
| Eisai INC. | $150.38 | 2019-2024 | |
| Amgen INC. | $119.79 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $117.57 | 2021-2024 | Ultomiris |
| Horizon Therapeutics Plc | $114.98 | 2021-2023 | Uplizna |
| Lilly USA, LLC | $112.19 | 2019-2023 | Emgality |
| Biogen, INC. | $89.80 | 2019-2025 | Tysabri, Vumerity |
| Pfizer INC. | $88.42 | 2023-2024 | |
| Acadia Pharmaceuticals INC | $83.64 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $80.06 | 2023-2025 | Amvuttra, Onpattro |
| Merz Pharmaceuticals, LLC | $68.50 | 2023-2025 | Xeomin |
| Sk Life Science, INC. | $65.19 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $54.07 | 2025 | Ajovy, Austedo Xr |
| Genentech USA, INC. | $47.84 | 2025 | Ocrevus Zunovo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $46.27 | 2022-2023 | Fycompa |
| Takeda Pharmaceuticals U.S.A., INC. | $45.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $44.80 | 2021 | |
| Argenx US, INC. | $40.54 | 2024-2025 | Vyvgart Hytrulo |
| Tanabe Pharma America, INC. | $37.27 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $36.72 | 2022-2025 | |
| Csl Behring | $36.41 | 2019 | |
| Genzyme Corporation | $34.11 | 2020-2022 | |
| Kyowa Kirin, INC. | $29.30 | 2019 | |
| Vanda Pharmaceuticals INC. | $25.49 | 2024 | Ponvory |
| Neurelis, INC. | $25.33 | 2023 | Valtoco |
| Sunovion Pharmaceuticals INC. | $24.25 | 2021 | |
| Lundbeck LLC | $23.97 | 2022 | |
| Acorda Therapeutics, INC | $16.93 | 2019 | |
| Aucta Pharmaceuticals, INC. | $13.97 | 2025 | Motpoly Xr |
| Neurocrine Biosciences, INC. | $13.10 | 2021 | |
| Strongbridge US INC. | $12.97 | 2020 | |
| Greenwich Biosciences, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Michelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.